FURUKAWA Yusuke

FacultyDivisionofStemCellRegulation,CenterforMolecularMedicine
Job titleProfessorWeb site

Profile

Research Keywords

    Hematology, Molecular Biology, Molecular Oncology

Research Areas

  • Biological science / Molecular biology
  • Biological science / Cell biology
  • Clinical internal medicine / Hematology

Career

  •       Jichi Medical School
  •       Institute, Harvard Medical School
  •       Jichi Medical School
  •     Regulation, Jichi Medical School
  • Jichi Medical School
  • 1987
    -
    1988
    Research Associate, Division of Hemopoiesis,
  • 1988
    -
    1990
    Research Fellow, Dana-Farber Cancer
  • 1992
    -
    1999
    Assistant Professor, Division of Hemopoiesis,
  • 1999
    - Associate Professor, Division of Stem Cell
  • 2003
    - Professor, Division of Stem Cell Regulation,

Academic Background

  • -
    1982
    School of Medicine, University of Tsukuba (japan)

Academic Societies

  • American Society of Hematology
  • International Society for Experimental Hematology
  • American Association for the Advancement of Science
  • International Society of Hematology
  • ASBMB
Display all
Academic Societiesclose
  • American Society of Hematology
  • International Society for Experimental Hematology
  • American Association for the Advancement of Science
  • International Society of Hematology
  • ASBMB

Committee Career

  • 2000
    -
    2003
    International Society for Experimental Hematology Editorial Board
Display all
Committeeclose
  • 2000
    -
    2003
    International Society for Experimental Hematology Editorial Board

Research Activities

Papers(paper)

  • Lysine-specific demethylase 1 inhibitors prevent teratoma development from human induced pluripotent stem cells
    Osada N, Kikuchi J, Umehara T, Sato S, Urabe M, Abe T, Hayashi N, Sugitani M, Hanazono Y, Furukawa Y
    Oncotarget 9(5) Jan. 2018
  • Myeloma Cells Are Activated in Bone Marrow Microenvironment by the CD180/MD-1 Complex, Which Senses Lipopolysaccharide
    Kikuchi J, Kuroda Y, Koyama D, Osada N, Izumi T, Yasui H, Kawase T, Ichinohe T, Furukawa Y
    Cancer Research 78(7) 1766 Jan. 2018
  • [Involvement of innate immunity in the expansion of multiple myeloma cells and therapeutic intervention with lenalidomide].
    Furukawa Y, Kuroda Y, Kikuchi J
    [Rinsho ketsueki] The Japanese journal of clinical hematology Jan. 2018
  • Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines.
    Takahashi K, Inukai T, Imamura T, Yano M, Tomoyasu C, Lucas DM, Nemoto A, Sato H, Huang M, Abe M, Kagami K, Shinohara T, Watanabe A, Somazu S, Sugita K
    PloS one Dec. 2017
  • Cell adhesion-induced phosphorylation and inactivation of EZH2 confer drug resistance to acute myeloid leukemia cells.
    Kikuchi J, Kuroda Y, Koyama D, Furukawa Y
    International journal of hematology Nov. 2017
  • istone deacetylases as novel therapeutic targets for refractory and relapsed multiple myeloma
    Yusuke Furukawa
    Annals of Oncology 27(7) Nov. 2016
  • Corrigendum to "Interferon-α repressed telomerase along with G1-accumulation of Daudi cells" [Cancer Letters 142 (1) (1999) 23-30].
    Akiyama M, Iwase S, Horiguchi-Yamada J, Saito S, Furukawa Y, Yamada O, Mizoguchi H, Ohno T, Yamada H
    Cancer letters Jul. 2016
  • Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma.
    Furukawa Y, Kikuchi J
    International journal of hematology Jul. 2016
  • Epigenetic regulation of cell adhesion-mediated drug resistance acquisition in multiple myeloma.
    Furukawa Y, Kikuchi J
    [Rinsho ketsueki] The Japanese journal of clinical hematology May 2016
  • Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.
    Nemoto A, Saida S, Kato I, Kikuchi J, Furukawa Y, Maeda Y, Akahane K, Honna-Oshiro H, Goi K, Kagami K, Kimura S, Sato Y, Okabe S, Niwa A, Watanabe K, Inukai T
    Molecular cancer therapeutics Dec. 2015
Display all
Papers(paper)close
  • Lysine-specific demethylase 1 inhibitors prevent teratoma development from human induced pluripotent stem cells
    Osada N, Kikuchi J, Umehara T, Sato S, Urabe M, Abe T, Hayashi N, Sugitani M, Hanazono Y, Furukawa Y
    Oncotarget 9(5) Jan. 2018
  • Myeloma Cells Are Activated in Bone Marrow Microenvironment by the CD180/MD-1 Complex, Which Senses Lipopolysaccharide
    Kikuchi J, Kuroda Y, Koyama D, Osada N, Izumi T, Yasui H, Kawase T, Ichinohe T, Furukawa Y
    Cancer Research 78(7) 1766 Jan. 2018
  • [Involvement of innate immunity in the expansion of multiple myeloma cells and therapeutic intervention with lenalidomide].
    Furukawa Y, Kuroda Y, Kikuchi J
    [Rinsho ketsueki] The Japanese journal of clinical hematology Jan. 2018
  • Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines.
    Takahashi K, Inukai T, Imamura T, Yano M, Tomoyasu C, Lucas DM, Nemoto A, Sato H, Huang M, Abe M, Kagami K, Shinohara T, Watanabe A, Somazu S, Sugita K
    PloS one Dec. 2017
  • Cell adhesion-induced phosphorylation and inactivation of EZH2 confer drug resistance to acute myeloid leukemia cells.
    Kikuchi J, Kuroda Y, Koyama D, Furukawa Y
    International journal of hematology Nov. 2017
  • istone deacetylases as novel therapeutic targets for refractory and relapsed multiple myeloma
    Yusuke Furukawa
    Annals of Oncology 27(7) Nov. 2016
  • Corrigendum to "Interferon-α repressed telomerase along with G1-accumulation of Daudi cells" [Cancer Letters 142 (1) (1999) 23-30].
    Akiyama M, Iwase S, Horiguchi-Yamada J, Saito S, Furukawa Y, Yamada O, Mizoguchi H, Ohno T, Yamada H
    Cancer letters Jul. 2016
  • Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma.
    Furukawa Y, Kikuchi J
    International journal of hematology Jul. 2016
  • Epigenetic regulation of cell adhesion-mediated drug resistance acquisition in multiple myeloma.
    Furukawa Y, Kikuchi J
    [Rinsho ketsueki] The Japanese journal of clinical hematology May 2016
  • Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.
    Nemoto A, Saida S, Kato I, Kikuchi J, Furukawa Y, Maeda Y, Akahane K, Honna-Oshiro H, Goi K, Kagami K, Kimura S, Sato Y, Okabe S, Niwa A, Watanabe K, Inukai T
    Molecular cancer therapeutics Dec. 2015
  • Soluble αKlotho as a candidate for the biomarker of aging.
    Koyama D, Sato Y, Aizawa M, Maki T, Kurosawa M, Kuro-o M, Furukawa Y
    Biochemical and biophysical research communications Oct. 2015
  • Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.
    Kikuchi J, Koyama D, Wada T, Izumi T, Hofgaard PO, Bogen B, Furukawa Y
    The Journal of clinical investigation 125(12) 4375-4390 Oct. 2015
  • Overexpression of the Shortest Isoform of Histone Demethylase LSD1 Primes Hematopoietic Stem Cells for Malignant Transformation.
    Wada, T., Koyama, D., Kikuchi, J., Honda, H. and Furukawa, Y.
    Blood 125 3731-3746 Jun. 2015
  • Molecular Pathogenesis of Multiple Myeloma
    Furukawa Y and Kikuchi J
    Int. J. Clin. Oncol.(20) 413-422 May 2015
  • Overexpression of the shortest isoform of histone demethylase LSD1 primes hematopoietic stem cells for malignant transformation.
    Wada T, Koyama D, Kikuchi J, Honda H, Furukawa Y
    Blood Apr. 2015
  • Arf Tumor Suppressor Disrupts the Oncogenic Positive Feedback Loop Including c-Myc and DDX5.
    Tago, K., Funakoshi-Tago, M., Itoh, H., Furukawa, Y., Kikuchi, J., Kato, T., Suzuki, K. and Yanagisawa, K.
    Oncogene 34 310-318 Feb. 2015
  • [The mechanisms of drug resistance via the interaction of myeloma cells with stromal cells].
    Kikuchi J, Furukawa Y
    Nihon rinsho. Japanese journal of clinical medicine 73 57-61 Jan. 2015
  • Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.
    Kikuchi J, Koyama D, Mukai HY, Furukawa Y
    International journal of hematology 99 726-736 Jun. 2014
  • [DNA methyltransferase inhibitors * histone deacetylase inhibitors].
    Kikuchi J, Furukawa Y
    Nihon rinsho. Japanese journal of clinical medicine 72 1136-1142 Jun. 2014
  • Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies.
    Hiraoka N, Kikuchi J, Yamauchi T, Koyama D, Wada T, Uesawa M, Akutsu M, Mori S, Nakamura Y, Ueda T, Kano Y, Furukawa Y
    PLoS One 9 e90675 Mar. 2014
  • Proteasome Inhibitors Exert Cytotoxicity and Increase Chemosensitivity via Transcriptional Repression of Notch1 in T-cell Acute Lymphoblastic Leukemia.
    Koyama, D., Kikuchi, J., Hiraoka, N., Wada, T., Kurosawa, H., Chiba, S. and Furukawa, Y.
    Leukemia 28 1216-1226 Jan. 2014
  • Romidepsin overcomes cell adhesion-mediated drug resistance in multiple myeloma cells.
    Sripayap P, Nagai T, Hatano K, Kikuchi J, Furukawa Y, Ozawa K
    Acta haematologica 132 1-4 2014
  • Alkylating agents induce histone H3K18 hyperacetylation and potentiate HDAC inhibitor-mediated global histone acetylation and cytotoxicity in mantle cell lymphoma.
    Hiraoka N, Kikuchi J, Koyama D, Wada T, Mori S, Nakamura Y, Furukawa Y
    Blood cancer journal Dec. 2013
  • [Molecular oncogenesis of multiple myeloma].
    Furukawa Y
    [Rinsho ketsueki] The Japanese journal of clinical hematology 54 1867-1875 Oct. 2013
  • The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.
    Kikuchi J, Yamada S, Koyama D, Wada T, Nobuyoshi M, Izumi T, Akutsu M, Kano Y, Furukawa Y
    The Journal of biological chemistry 288 25593-25602 Aug. 2013
  • [How to overcome the cell adhesion-mediated drug resistance in multiple myeloma].
    Furukawa Y, Kikuchi J
    [Rinsho ketsueki] The Japanese journal of clinical hematology 54 513-521 Jun. 2013
  • Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding.
    Kikuchi J, Shibayama N, Yamada S, Wada T, Nobuyoshi M, Izumi T, Akutsu M, Kano Y, Sugiyama K, Ohki M, Park SY, Furukawa Y
    PloS one 8 e60649 Apr. 2013
  • Promoter methylation confers kidney-specific expression of the Klotho gene.
    Azuma M, Koyama D, Kikuchi J, Yoshizawa H, Thasinas D, Shiizaki K, Kuro-o M, Furukawa Y, Kusano E
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology 26 4264-4274 Oct. 2012
  • Reduced histone H3K9 acetylation of clock genes and abnormal glucose metabolism in ob/ob mice.
    Ishikawa-Kobayashi E, Ushijima K, Ando H, Maekawa T, Takuma M, Furukawa Y, Fujimura A
    Chronobiology international 29 982-993 Oct. 2012
  • BCR-ABL regulates death receptor expression for TNF-related apoptosis-inducing ligand (TRAIL) in Philadelphia chromosome-positive leukemia.
    Kuroda I, Inukai T, Zhang X, Kikuchi J, Furukawa Y, Nemoto A, Akahane K, Hirose K, Honna-Oshiro H, Goi K, Kagami K, Yagita H, Tauchi T, Maeda Y, Sugita K
    Oncogene Jun. 2012
  • Latexin regulates the abundance of multiple cellular proteins in hematopoietic stem cells.
    Mitsunaga K, Kikuchi J, Wada T, Furukawa Y
    Journal of cellular physiology 227 1138-1147 Mar. 2012
  • Histone deacetylase 1 enhances microRNA processing via deacetylation of DGCR8.
    Wada T, Kikuchi J, Furukawa Y
    EMBO reports 13 142-149 Feb. 2012
  • [Mechanisms of action and clinical effectiveness of the newly approved anti-cancer drug bendamustine].
    Furukawa Y, Hiraoka N, Wada T, Kikuchi J, Kano Y
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica 138 26-32 Jul. 2011
  • Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system.
    Tauchi T, Kizaki M, Okamoto S, Tanaka H, Tanimoto M, Inokuchi K, Murayama T, Saburi Y, Hino M, Tsudo M, Shimomura T, Isobe Y, Oshimi K, Dan K, TARGET Investigators
    Leukemia research Dec. 2010
  • Vinculin is indispensable for repopulation by hematopoietic stem cells, independent of integrin function.
    Ohmori T, Kashiwakura Y, Ishiwata A, Madoiwa S, Mimuro J, Furukawa Y, Sakata Y
    The Journal of biological chemistry 285 31763-31773 Oct. 2010
  • Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19).
    Hirose K, Inukai T, Kikuchi J, Furukawa Y, Ikawa T, Kawamoto H, Oram SH, G?ttgens B, Kiyokawa N, Miyagawa Y, Okita H, Akahane K, Zhang X, Kuroda I, Honna H, Kagami K, Goi K, Kurosawa H, Look AT, Matsui H, Inaba T, Sugita K
    Blood 116 962-970 Aug. 2010
  • HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.
    Shimizu R, Kikuchi J, Wada T, Ozawa K, Kano Y, Furukawa Y
    Leukemia Aug. 2010
  • Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma.
    Kikuchi J, Wada T, Shimizu R, Izumi T, Akutsu M, Mitsunaga K, Noborio-Hatano K, Nobuyoshi M, Ozawa K, Kano Y, Furukawa Y
    Blood 116 406-417 Jul. 2010
  • MSK1 activation in acute myeloid leukemia cells with FLT3 mutations.
    Odgerel T, Kikuchi J, Wada T, Shimizu R, Kano Y, Furukawa Y
    Leukemia Apr. 2010
  • Up-regulation of survivin by the E2A-HLF chimera is indispensable for the survival of t(17;19)-positive leukemia cells.
    Okuya M, Kurosawa H, Kikuchi J, Furukawa Y, Matsui H, Aki D, Matsunaga T, Inukai T, Goto H, Altura RA, Sugita K, Arisaka O, Look AT, Inaba T
    The Journal of biological chemistry 285 1850-1860 Jan. 2010
  • Schedule-dependent synergism and antagonism between pemetrexed and docetaxel in human lung cancer cell lines in vitro.
    Kano Y, Tanaka M, Akutsu M, Mori K, Yazawa Y, Mano H, Furukawa Y
    Cancer chemotherapy and pharmacology 64 1129-1137 Nov. 2009
  • The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.
    Tanaka M, Kano Y, Akutsu M, Tsunoda S, Izumi T, Yazawa Y, Miyawaki S, Mano H, Furukawa Y
    Anticancer research 29 4589-4596 Nov. 2009
  • Expression levels of histone deacetylases determine the cell fate of hematopoietic progenitors.
    Wada T, Kikuchi J, Nishimura N, Shimizu R, Kitamura T, Furukawa Y
    The Journal of biological chemistry 284 30673-30683 Oct. 2009
  • A novel missense mutation of ABCA1 in transmembrane alpha-helix in a Japanese patient with Tangier disease.
    Maekawa M, Kikuchi J, Kotani K, Nagao K, Odgerel T, Ueda K, Kawano M, Furukawa Y, Sakurabayashi I
    Atherosclerosis 206 216-222 Sep. 2009
  • Ablation of neutral cholesterol ester hydrolase 1 accelerates atherosclerosis.
    Sekiya M, Osuga J, Nagashima S, Ohshiro T, Igarashi M, Okazaki H, Takahashi M, Tazoe F, Wada T, Ohta K, Takanashi M, Kumagai M, Nishi M, Takase S, Yahagi N, Yagyu H, Ohashi K, Nagai R, Kadowaki T, Furukawa Y, Ishibashi S
    Cell metabolism 10 219-228 Sep. 2009
  • Vasoactive intestinal peptide and inflammatory cytokines enhance vascular endothelial growth factor production from epidermal keratinocytes.
    Kakurai M, Demitsu T, Umemoto N, Kobayashi Y, Inoue-Narita T, Fujita N, Ohtsuki M, Furukawa Y
    The British journal of dermatology Aug. 2009
  • Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.
    Sanada M, Suzuki T, Shih LY, Otsu M, Kato M, Yamazaki S, Tamura A, Honda H, Sakata-Yanagimoto M, Kumano K, Oda H, Yamagata T, Takita J, Gotoh N, Ogawa S
    Nature Jul. 2009
  • Transactivation of RON receptor tyrosine kinase by interaction with PDGF receptor beta during steady-state growth of human mesangial cells.
    Kobayashi T, Furukawa Y, Kikuchi J, Ito C, Miyata Y, Muto S, Tanaka A, Kusano E
    Kidney international 75 1173-1183 Jun. 2009
  • Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
    Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M, Nobuyoshi M, Oh I, Sato K, Suzuki T, Ozaki K, Mori M, Nagai T, Muroi K, Kano Y, Ozawa K
    Oncogene Oct. 2008
  • [Epigenetics in hematological disorders].
    Furukawa Y
    [Rinsho ketsueki] The Japanese journal of clinical hematology 49 1472-1482 Oct. 2008
  • Ras-mediated up-regulation of survivin expression in cytokine-dependent murine pro-B lymphocytic cells.
    Shinjyo T, Kurosawa H, Miyagi J, Ohama K, Masuda M, Nagasaki A, Matsui H, Inaba T, Furukawa Y, Takasu N
    The Tohoku journal of experimental medicine 216 25-34 Sep. 2008
  • Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma.
    Murakami T, Sato A, Chun NA, Hara M, Naito Y, Kobayashi Y, Kano Y, Ohtsuki M, Furukawa Y, Kobayashi E
    The Journal of investigative dermatology 128 1506-1516 Jun. 2008
  • Fhit-deficient hematopoietic stem cells survive hydroquinone exposure carrying precancerous changes.
    Ishii H, Mimori K, Ishikawa K, Okumura H, Pichiorri F, Druck T, Inoue H, Vecchione A, Saito T, Mori M, Huebner K
    Cancer research May 2008
  • Cholesterol reduction and atherosclerosis inhibition by bezafibrate in low-density lipoprotein receptor knockout mice.
    Inaba T, Yagyu H, Itabashi N, Tazoe F, Fujita N, Nagashima S, Okada K, Okazaki M, Furukawa Y, Ishibashi S
    Hypertension research : official journal of the Japanese Society of Hypertension 31 999-1005 May 2008
  • CD43, but not P-selectin glycoprotein ligand-1, functions as an E-selectin counter-receptor in human pre-B-cell leukemia NALL-1.
    Nonomura C, Kikuchi J, Kiyokawa N, Ozaki H, Mitsunaga K, Ando H, Kanamori A, Kannagi R, Fujimoto J, Muroi K, Furukawa Y, Nakamura M
    Cancer research 68 790-799 Feb. 2008
  • Long-term results of dose-intensive chemotherapy with G-CSF support (TCC-NHL-91) for advanced intermediate-grade non-Hodgkin's lymphoma: a review of 59 consecutive cases treated at a single institute.
    Akutsu M, Tsunoda S, Izumi T, Tanaka M, Katano S, Inoue K, Igarashi S, Hirabayashi K, Furukawa Y, Ohmine K, Sato K, Kobayashi H, Ozawa K, Kirito K, Nagashima T, Teramukai S, Fukushima M, Kano Y
    Oncology research 17 137-149 Jan. 2008
  • Activation of focal adhesion kinase in detached human epidermal cancer cells and their long-term survival might be associated with cell surface expression of laminin-5.
    Katayama H, Yamane Y, Furukawa Y, Kitagawa S, Nakamura Y, Yoshino K
    Acta dermato-venereologica 88 100-107 2008
  • The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations.
    Odgerel T, Kikuchi J, Wada T, Shimizu R, Futaki K, Kano Y, Furukawa Y
    Oncogene Dec. 2007
  • E2F-6 suppresses growth-associated apoptosis of human hematopoietic progenitor cells by counteracting proapoptotic activity of E2F-1.
    Kikuchi J, Shimizu R, Wada T, Ando H, Nakamura M, Ozawa K, Furukawa Y
    Stem cells (Dayton, Ohio) 25 2439-2447 Oct. 2007
  • Rad9 modulates the P21WAF1 pathway by direct association with p53.
    Ishikawa K, Ishii H, Murakumo Y, Mimori K, Kobayashi M, Yamamoto K, Mori M, Nishino H, Furukawa Y, Ichimura K
    BMC molecular biology 8 37 May 2007
  • Fez1/Lzts1 absence impairs Cdk1/Cdc25C interaction during mitosis and predisposes mice to cancer development.
    Vecchione A, Baldassarre G, Ishii H, Nicoloso MS, Belletti B, Petrocca F, Zanesi N, Fong LY, Battista S, Guarnieri D, Baffa R, Alder H, Farber JL, Croce CM
    Cancer cell Mar. 2007
  • Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines.
    Furukawa Y, Vu HA, Akutsu M, Odgerel T, Izumi T, Tsunoda S, Matsuo Y, Kirito K, Sato Y, Mano H, Kano Y
    Leukemia Mar. 2007
  • Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.
    Kano Y, Akutsu M, Tsunoda S, Izumi T, Kobayashi H, Mano H, Furukawa Y
    Investigational new drugs 25 31-40 Feb. 2007
  • Fhit modulates the DNA damage checkpoint response.
    Ishii H, Mimori K, Inoue H, Inageta T, Ishikawa K, Semba S, Druck T, Trapasso F, Tani K, Vecchione A, Croce CM, Mori M, Huebner K
    Cancer research Dec. 2006
  • Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
    Sutheesophon K, Kobayashi Y, Takatoku MA, Ozawa K, Kano Y, Ishii H, Furukawa Y
    Acta haematologica 115 78-90 Jan. 2006
  • Schedule-dependent interactions between pemetrexed and cisplatin in human carcinoma cell lines in vitro.
    Kano Y, Akutsu M, Tsunoda S, Izumi T, Kobayashi H, Inoue K, Mori K, Fujii H, Mano H, Odgerel T, Furukawa Y
    Oncology research 16 85-95 Jan. 2006
  • Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma.
    Kobayashi Y, Ohtsuki M, Murakami T, Kobayashi T, Sutheesophon K, Kitayama H, Kano Y, Kusano E, Nakagawa H, Furukawa Y
    Oncogene Jan. 2006
  • Frag1, a homolog of alternative replication factor C subunits, links replication stress surveillance with apoptosis.
    Ishii H, Inageta T, Mimori K, Saito T, Sasaki H, Isobe M, Mori M, Croce CM, Huebner K, Ozawa K, Furukawa Y
    Proceedings of the National Academy of Sciences of the United States of America 102 9655-9660 Jul. 2005
  • Methylation silencing of the Apaf-1 gene in acute leukemia.
    Furukawa Y, Sutheesophon K, Wada T, Nishimura M, Saito Y, Ishii H, Furukawa Y
    Molecular cancer research : MCR 3 325-334 Jun. 2005
  • Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).
    Sutheesophon K, Nishimura N, Kobayashi Y, Furukawa Y, Kawano M, Itoh K, Kano Y, Ishii H, Furukawa Y
    Journal of cellular physiology 203 387-397 May 2005
  • Differential roles of E-type cyclins during transformation of murine E2F-1-deficient cells.
    Ishii H, Mimori K, Yoshikawa Y, Mori M, Furukawa Y, Vecchione A
    DNA and cell biology 24 173-179 Mar. 2005
  • Components of DNA damage checkpoint pathway regulate UV exposure-dependent alterations of gene expression of FHIT and WWOX at chromosome fragile sites.
    Ishii H, Mimori K, Inageta T, Murakumo Y, Vecchione A, Mori M, Furukawa Y
    Molecular cancer research : MCR 3 130-138 Mar. 2005
  • Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro.
    Kano Y, Akutsu M, Tsunoda S, Izumi T, Mori K, Fujii H, Yazawa Y, Mano H, Furukawa Y
    Cancer chemotherapy and pharmacology 54 505-513 Dec. 2004
  • Differentially expressed genes execute zinc-induced apoptosis in precancerous esophageal epithelium of zinc-deficient rats.
    Ishii H, Vecchione A, Furukawa Y, Croce CM, Huebner K, Fong LY
    Oncogene 23 8040-8048 Oct. 2004
  • Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect.
    Kawano T, Horiguchi-Yamada J, Iwase S, Akiyama M, Furukawa Y, Kan Y, Yamada H
    Anticancer research 24 2705-2712 Sep. 2004
  • Role of cyclins in cAMP inhibition of glomerular mesangial cell proliferation.
    Ito C, Yamamoto H, Furukawa Y, Takeda S, Akimoto T, Iimura O, Ando Y, Asano Y, Kusano E
    Clinical science (London, England : 1979) 107 81-87 Jul. 2004
  • Ectopic cyclin D1 expression blocks STI571-induced erythroid differentiation of K562 cells.
    Kawano T, Horiguchi-Yamada J, Saito S, Iwase S, Furukawa Y, Kano Y, Yamada H
    Leukemia research 28 623-629 Jun. 2004
  • Effect of exogenous E2F-1 on the expression of common chromosome fragile site genes, FHIT and WWOX.
    Ishii H, Mimori K, Vecchione A, Sutheesophon K, Fujiwara T, Mori M, Furukawa Y
    Biochemical and biophysical research communications 316 1088-1093 Apr. 2004
  • Alterations of common chromosome fragile sites in hematopoietic malignancies.
    Ishii H, Furukawa Y
    International journal of hematology 79 238-242 Apr. 2004
  • Inactivation of ERK accelerates erythroid differentiation of K562 cells induced by herbimycin A and STI571 while activation of MEK1 interferes with it.
    Kawano T, Horiguchi-Yamada J, Iwase S, Furukawa Y, Kano Y, Yamada H
    Molecular and cellular biochemistry 258 25-33 Mar. 2004
  • Cancer prevention and therapy in a preclinical mouse model: impact of FHIT viruses.
    Ishii H, Vecchione A, Fong LY, Zanesi N, Trapasso F, Furukawa Y, Baffa R, Huebner K, Croce CM
    Current gene therapy 4 53-63 Mar. 2004
  • Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies.
    Ishii H, Vecchione A, Furukawa Y, Sutheesophon K, Han SY, Druck T, Kuroki T, Trapasso F, Nishimura M, Saito Y, Ozawa K, Croce CM, Huebner K, Furukawa Y
    Molecular cancer research : MCR 1 940-947 Nov. 2003
  • Alteration of the fragile histidine triad gene early in carcinogenesis: an update.
    Ishii H, Ozawa K, Furukawa Y
    Journal of experimental therapeutics & oncology 3 291-296 Nov. 2003
  • Suppression of ARG kinase activity by STI571 induces cell cycle arrest through up-regulation of CDK inhibitor p18/INK4c.
    Nishimura N, Furukawa Y, Sutheesophon K, Nakamura M, Kishi K, Okuda K, Sato Y, Kano Y
    Oncogene 22 4074-4082 Jun. 2003
  • A novel I-branching beta-1,6-N-acetylglucosaminyltransferase involved in human blood group I antigen expression.
    Inaba N, Hiruma T, Togayachi A, Iwasaki H, Wang XH, Furukawa Y, Sumi R, Kudo T, Fujimura K, Iwai T, Gotoh M, Nakamura M, Narimatsu H
    Blood 101 2870-2876 Apr. 2003
  • Identification of novel p53-binding proteins by biomolecular interaction analysis combined with tandem mass spectrometry.
    Kikuchi J, Furukawa Y, Hayashi N
    Molecular biotechnology 23 203-212 Mar. 2003
  • Modulation of the erythropoietin-induced proliferative pathway by cAMP in vascular smooth muscle cells.
    Ito C, Kusano E, Furukawa Y, Yamamoto H, Takeda S, Akimoto T, Iimura O, Ando Y, Asano Y
    American journal of physiology. Cell physiology 283 C1715-21 Dec. 2002
  • Vasoactive intestinal peptide and cytokines enhance stem cell factor production from epidermal keratinocytes DJM-1.
    Kakurai M, Fujita N, Kiyosawa T, Inoue T, Ishibashi S, Furukawa Y, Demitsu T, Nakagawa H
    The Journal of investigative dermatology 119 1183-1188 Nov. 2002
  • Apaf-1 is a mediator of E2F-1-induced apoptosis.
    Furukawa Y, Nishimura N, Furukawa Y, Satoh M, Endo H, Iwase S, Yamada H, Matsuda M, Kano Y, Nakamura M
    The Journal of biological chemistry 277 39760-39768 Oct. 2002
  • Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro.
    Akutsu M, Furukawa Y, Tsunoda S, Izumi T, Ohmine K, Kano Y
    Leukemia Sep. 2002
  • Differences in E2F subunit expression in quiescent and proliferating vascular smooth muscle cells.
    Fujita N, Furukawa Y, Itabashi N, Okada K, Saito T, Ishibashi S
    American journal of physiology. Heart and circulatory physiology 283 H204-12 Jul. 2002
  • Hyperglycemia enhances VSMC proliferation with NF-kappaB activation by angiotensin II and E2F-1 augmentation by growth factors.
    Fujita N, Furukawa Y, Du J, Itabashi N, Fujisawa G, Okada K, Saito T, Ishibashi S
    Molecular and cellular endocrinology 192 75-84 Jun. 2002
  • [Effectiveness of prolonged oral administration of low-dose etoposide in a case of malignant lymphoma in the mesenterium].
    Sato T, Yanagihara M, Sato K, Nozawa T, Furukawa Y, Imanishi H, Kouzuma T
    Gan to kagaku ryoho. Cancer & chemotherapy 29 959-962 Jun. 2002
  • Phosphorylation of Fanconi anemia protein, FANCA, is regulated by Akt kinase.
    Otsuki T, Nagashima T, Komatsu N, Kirito K, Furukawa Y, Kobayashi Si S, Liu JM, Ozawa K
    Biochemical and biophysical research communications 291 628-634 Mar. 2002
  • Cell cycle control genes and hematopoietic cell differentiation.
    Furukawa Y
    Leukemia & lymphoma 43 225-231 Feb. 2002
  • Fanconi anemia protein, FANCA, associates with BRG1, a component of the human SWI/SNF complex.
    Otsuki T, Furukawa Y, Ikeda K, Endo H, Yamashita T, Shinohara A, Iwamatsu A, Ozawa K, Liu JM
    Human molecular genetics Nov. 2001
  • Antitumor effect of beta2-microglobulin in leukemic cell-bearing mice via apoptosis-inducing activity: activation of caspase-3 and nuclear factor-kappaB.
    Mori M, Terui Y, Tanaka M, Tomizuka H, Mishima Y, Ikeda M, Kasahara T, Uwai M, Ueda M, Inoue R, Itoh T, Yamada M, Hayasawa H, Furukawa Y, Ishizaka Y, Hatake K
    Cancer research Jun. 2001
  • Vasoactive intestinal peptide regulates its receptor expression and functions of human keratinocytes via type I vasoactive intestinal peptide receptors.
    Kakurai M, Fujita N, Murata S, Furukawa Y, Demitsu T, Nakagawa H
    The Journal of investigative dermatology May 2001
  • In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.
    Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, Furukawa Y
    Blood Apr. 2001
  • Stimulation of GATA-2 as a mechanism of hydrogen peroxide suppression in hypoxia-induced erythropoietin gene expression.
    Tabata M, Tarumoto T, Ohmine K, Furukawa Y, Hatake K, Ozawa K, Hasegawa Y, Mukai H, Yamamoto M, Imagawa S
    Journal of cellular physiology Feb. 2001
  • Schedule-dependent synergism and antagonism between raltitrexed ("Tomudex") and methotrexate in human colon cancer cell lines in vitro.
    Kano Y, Akutsu M, Tsunoda S, Suzuki K, Yazawa Y, Furukawa Y
    Japanese journal of cancer research : Gann Jan. 2001
  • Downregulation of an AIM-1 kinase couples with megakaryocytic polyploidization of human hematopoietic cells.
    Kawasaki A, Matsumura I, Miyagawa Ji, Ezoe S, Tanaka H, Terada Y, Tatsuka M, Machii T, Miyazaki H, Furukawa Y, Kanakura Y
    The Journal of cell biology Jan. 2001
  • Lineage-specific regulation of cell cycle control gene expression during haematopoietic cell differentiation.
    Furukawa Y, Kikuchi J, Nakamura M, Iwase S, Yamada H, Matsuda M
    British journal of haematology Sep. 2000
  • Phosphorylation of Bcl-2 protein by CDC2 kinase during G2/M phases and its role in cell cycle regulation.
    Furukawa Y, Iwase S, Kikuchi J, Terui Y, Nakamura M, Yamada H, Kano Y, Matsuda M
    The Journal of biological chemistry Jul. 2000
  • A simple semisolid subtraction method using carbodiimide-coated microplates.
    Kikuchi J, Furukawa Y, Suzuki O, Hayashi N, Nakamura M, Morita M, Matsuda M
    Molecular biotechnology Jul. 2000
  • Three-dimensional matrix suppresses E2F-controlled gene expression in glomerular mesangial cells.
    Tsuboi N, Yoshida H, Kawamura T, Furukawa Y, Hosoya T, Yamada H
    Kidney international Apr. 2000
  • In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
    Kano Y, Akutsu M, Tsunoda S, Suzuki K, Ichikawa A, Furukawa Y, Bai L, Kon K
    Leukemia Mar. 2000
  • Schedule-dependent interaction between raltitrexed and 5-fluorouracil in human colon cancer cell lines in vitro.
    Kano Y, Akutsu M, Suzuki K, Yazawa Y, Tsunoda S, Furukawa Y
    Oncology research Jan. 2000
  • Regulation of macrophage-specific gene expression by degenerated lipoproteins.
    Furukawa Y, Kubo N, Kikuchi J, Tokura A, Fujita N, Sakurabayashi I
    Electrophoresis Jan. 2000
  • Induction of ubiquitin-conjugating enzyme by aggregated low density lipoprotein in human macrophages and its implications for atherosclerosis.
    Kikuchi J, Furukawa Y, Kubo N, Tokura A, Hayashi N, Nakamura M, Matsuda M, Sakurabayashi I
    Arteriosclerosis, thrombosis, and vascular biology Jan. 2000
  • Simultaneous core 2 beta1-->6N-acetylglucosaminyltransferase up-regulation and sialyl-Le(X) expression during activation of human tonsillar B lymphocytes.
    Nakamura M, Ishida T, Kikuchi J, Furukawa Y, Matsuda M
    FEBS letters Dec. 1999
  • Beta(2)-microglobulin identified as an apoptosis-inducing factor and its characterization.
    Mori M, Terui Y, Ikeda M, Tomizuka H, Uwai M, Kasahara T, Kubota N, Itoh T, Mishima Y, Douzono-Tanaka M, Yamada M, Shimamura S, Kikuchi J, Hatake K
    Blood Oct. 1999
  • Failure of cdc2 promoter activation and G(2)/M transition by ANG II and AVP in vascular smooth muscle cells.
    Fujita N, Furukawa Y, Itabashi N, Tsuboi Y, Matsuda M, Okada K, Saito T
    The American journal of physiology Aug. 1999
  • Interferon-alpha repressed telomerase along with G1-accumulation of Daudi cells.
    Akiyama M, Iwase S, Horiguchi-Yamada J, Saito S, Furukawa Y, Yamada O, Mizoguchi H, Ohno T, Yamada H
    Cancer letters Jul. 1999
  • Defective binding of IRFs to the initiator element of interleukin-1beta-converting enzyme (ICE) promoter in an interferon-resistant Daudi subline.
    Iwase S, Furukawa Y, Kikuchi J, Saito S, Nakamura M, Nakayama R, Horiguchi-Yamada J, Yamada H
    FEBS letters May 1999
  • Transcriptional repression of the E2F-1 gene by interferon-alpha is mediated through induction of E2F-4/pRB and E2F-4/p130 complexes.
    Furukawa Y, Iwase S, Kikuchi J, Nakamura M, Yamada H, Matsuda M
    Oncogene Mar. 1999
  • UDP-GlcNAc:Galbeta1-->3GalNAc (GlcNAc to GalNAc) beta1-->6N-acetylglucosaminyltransferase holds a key role on the control of CD15s expression in human pre-B lymphoid cell lines.
    Nakamura M, Furukawa Y, Sasaki R, Masuyama J, Kikuchi J, Iwase S, Kudo T, Narimatsu H, Asakura S, Fujiwara S, Inokuchi J
    Glycobiology Jan. 1999
  • Single glycosyltransferase, core 2 beta1-->6-N-acetylglucosaminyltransferase, regulates cell surface sialyl-Lex expression level in human pre-B lymphocytic leukemia cell line KM3 treated with phorbolester.
    Nakamura M, Kudo T, Narimatsu H, Furukawa Y, Kikuchi J, Asakura S, Yang W, Iwase S, Hatake K, Miura Y
    The Journal of biological chemistry Oct. 1998
  • A Janus kinase inhibitor, JAB, is an interferon-gamma-inducible gene and confers resistance to interferons.
    Sakamoto H, Yasukawa H, Masuhara M, Tanimura S, Sasaki A, Yuge K, Ohtsubo M, Ohtsuka A, Fujita T, Ohta T, Furukawa Y, Iwase S, Yamada H, Yoshimura A
    Blood Sep. 1998
  • Cell cycle regulation of hematopoietic stem cells.
    Furukawa Y
    Human cell Jun. 1998
  • A novel variant of acute myelomonocytic leukemia carrying t(3;12)(q26;p13) with characteristics of 3q21q26 syndrome.
    Iwase S, Furukawa Y, Horiguchi-Yamada J, Nemoto T, Takahara S, Kawano T, Sekikawa T, Ito K, Yamazaki Y, Kikuchi J, Morishita K, Yamada H
    International journal of hematology Jun. 1998
  • [Retrospective analysis of elderly patients > or = 60 years of age with acute leukemia].
    Tabata M, Yoshida M, Izumi T, Kawano C, Kuribara R, Toshima M, Omine K, Takatoku M, Uchida M, Kirito K, Miyazato A, Takahashi H, Hoshino M, Terui Y, Miura Y
    [Rinsho ketsueki] The Japanese journal of clinical hematology Mar. 1998
  • Bcl-x is a regulatory factor of apoptosis and differentiation in megakaryocytic lineage cells.
    Terui Y, Furukawa Y, Kikuchi J, Iwase S, Hatake K, Miura Y
    Experimental hematology Mar. 1998
  • Human monocyte-endothelial cell interaction induces platelet-derived growth factor expression.
    Funayama H, Ikeda U, Takahashi M, Sakata Y, Kitagawa S, Takahashi Y, Masuyama J, Furukawa Y, Miura Y, Kano S, Matsuda M, Shimada K
    Cardiovascular research Jan. 1998
  • Cell cycle control during hematopoietic cell differentiation.
    Furukawa Y
    Human cell Sep. 1997
  • CMP-NeuAc:Gal beta 1-->4GlcNAc alpha 2-->6sialyltransferase catalyzes NeuAc transfer to glycolipids.
    Nakamura M, Tsunoda A, Yanagisawa K, Furukawa Y, Kikuchi J, Iwase S, Sakai T, Larson G, Saito M
    Journal of lipid research Sep. 1997
  • Regulatory effects of aggregated LDL on apoptosis during foam cell formation of human peripheral blood monocytes.
    Kubo N, Kikuchi J, Furukawa Y, Sakai T, Ohta H, Iwase S, Yamada H, Sakurabayashi I
    FEBS letters Jun. 1997
  • Polyploidization and functional maturation are two distinct processes during megakaryocytic differentiation: involvement of cyclin-dependent kinase inhibitor p21 in polyploidization.
    Kikuchi J, Furukawa Y, Iwase S, Terui Y, Nakamura M, Kitagawa S, Kitagawa M, Komatsu N, Miura Y
    Blood Jun. 1997
  • Modulation of E2F activity is linked to interferon-induced growth suppression of hematopoietic cells.
    Iwase S, Furukawa Y, Kikuchi J, Nagai M, Terui Y, Nakamura M, Yamada H
    The Journal of biological chemistry May 1997
  • Chloroquine induces basophilic differentiation of HL-60 cells.
    Sasaki R, Furukawa Y, Okada K, Nakamura M, Yamane Y, Miura Y, Eguchi M
    Leukemia Apr. 1997
  • Antileukemic effect of interferon-alpha is mediated through down-modulation of E2F activity.
    Furukawa Y, Iwase S
    Leukemia Apr. 1997
  • Cell-cycle-dependent regulation of erythropoietin receptor gene.
    Komatsu N, Kirito K, Kashii Y, Furukawa Y, Kikuchi J, Suwabe N, Yamamoto M, Miura Y
    Blood Feb. 1997
  • The expression of ST2 gene in helper T cells and the binding of ST2 protein to myeloma-derived RPMI8226 cells.
    Yanagisawa K, Naito Y, Kuroiwa K, Arai T, Furukawa Y, Tomizuka H, Miura Y, Kasahara T, Tetsuka T, Tominaga S
    Journal of biochemistry Jan. 1997
  • Rapid internalization of exogenous ganglioside GM3 and its metabolism to ceramide in human myelogenous leukemia HL-60 cells compared with control ganglioside GM1.
    Nakamura M, Tsunoda A, Furukawa Y, Sakai T, Saito M
    FEBS letters Jan. 1997
  • Herbimycin A down-regulates messages of cyclin D1 and c-myc during erythroid differentiation of K562 cells.
    Yamada H, Iwase S, Nagai M, Nemoto T, Sekikawa T, Takahara S, Nakada S, Furukawa Y, Horiguchi-Yamada J
    International journal of hematology Dec. 1996
  • Transcriptional activation of the cdc2 gene is associated with Fas-induced apoptosis of human hematopoietic cells.
    Furukawa Y, Iwase S, Terui Y, Kikuchi J, Sakai T, Nakamura M, Kitagawa S, Kitagawa M
    The Journal of biological chemistry Nov. 1996
  • Tenascin-X expression in tumor cells and fibroblasts: glucocorticoids as negative regulators in fibroblasts.
    Sakai T, Furukawa Y, Chiquet-Ehrismann R, Nakamura M, Kitagawa S, Ikemura T, Matsumoto K
    Journal of cell science Aug. 1996
  • Interleukin-3-associated ganglioside GD1a is induced independently of normal interleukin-3 receptor in murine myelogenous leukaemia NFS60 cells transfected with the interleukin-3 gene.
    Nakamura M, Kirito K, Tsunoda A, Hara K, Furukawa Y, Saito M
    Glycoconjugate journal Apr. 1996
  • Up-regulation of VLA-5 expression during monocytic differentiation and its role in negative control of the survival of peripheral blood monocytes.
    Terui Y, Furukawa Y, Sakai T, Kikuchi J, Sugahara H, Kanakura Y, Kitagawa S, Miura Y
    Journal of immunology (Baltimore, Md. : 1950) Mar. 1996
  • Human monocyte-endothelial cell interaction induces synthesis of granulocyte-macrophage colony-stimulating factor.
    Takahashi M, Kitagawa S, Masuyama JI, Ikeda U, Kasahara T, Takahashi YI, Furukawa Y, Kano S, Shimada K
    Circulation Mar. 1996
  • Activation of human monocyte functions by tumor necrosis factor: rapid priming for enhanced release of superoxide and erythrophagocytosis, but no direct triggering of superoxide release.
    Kitagawa S, Yuo A, Yagisawa M, Azuma E, Yoshida M, Furukawa Y, Takahashi M, Masuyama J, Takaku F
    Experimental hematology Mar. 1996
  • [Retrospective analysis on 21 patients with follicular lymphoma]
    Izumi T, Imagawa S, Muroi K, Shimizu R, Takahashi H, Hoshino Y, Tomizuka H, Kawakami T, Toya K, Kurata H, Tsunoda J, Furukawa Y, Suzuki T, Komatsu N, Miura Y
    [Rinsho ketsueki] The Japanese journal of clinical hematology Jan. 1996
  • Combination chemotherapy of carboplatin and cytosine arabinoside for high-risk leukemia: a pilot study.
    Iwao N, Yoshida M, Hatake K, Hoshino Y, Hagiwara S, Tomizuka H, Shimizu R, Suzuki T, Furukawa Y, Komatsu N
    Leukemia research Dec. 1995
  • Biosynthesis of the so-called "a" and "asialo" pathway glycosphingolipids is differentially regulated in murine myelogenous leukemia NFS60 cells.
    Nakamura M, Sakai T, Furukawa Y, Kitagawa S, Sakoe K, Tsunoda A
    Biochemical and biophysical research communications Dec. 1995
  • Regulation of EGF-induced tenascin-C by steroids in tenascin-C-non-producing human carcinoma cells.
    Sakai T, Kawakatsu H, Furukawa Y, Saito M
    International journal of cancer Nov. 1995
  • Tenascin-C induction by the diffusible factor epidermal growth factor in stromal-epithelial interactions.
    Sakai T, Ohta M, Furukawa Y, Saga Y, Aizawa S, Kawakatsu H, Saito M
    Journal of cellular physiology Oct. 1995
  • Apoptosis during HL-60 cell differentiation is closely related to a G0/G1 cell cycle arrest.
    Terui Y, Furukawa Y, Kikuchi J, Saito M
    Journal of cellular physiology Jul. 1995
  • Over-expression and amplification of the CDC2 gene in leukaemia cells.
    Furukawa Y, Terui Y, Sakoe K, Ohta M, Kitagawa S, Miura Y, Saito M
    British journal of haematology May 1995
  • Tenascin-C induction in Whitlock-Witte culture: a relevant role of the thiol moiety in lymphoid-lineage differentiation.
    Sakai T, Ohta M, Kawakatsu H, Furukawa Y, Saito M
    Experimental cell research Apr. 1995
  • Preferential production of interleukin-1 beta over interleukin-1 receptor antagonist contributes to proliferation and suppression of apoptosis in leukemic cells.
    Furukawa Y, Kikuchi J, Terui Y, Kitagawa S, Ohta M, Miura Y, Saito M
    Japanese journal of cancer research : Gann Feb. 1995
  • Expression of differentiation-related phenotypes and apoptosis are independently regulated during myeloid cell differentiation.
    Terui Y, Furukawa Y, Sakoe K, Ohta M, Saito M
    Journal of biochemistry Jan. 1995
  • The role of cellular transcription factor E2F in the regulation of cdc2 mRNA expression and cell cycle control of human hematopoietic cells.
    Furukawa Y, Terui Y, Sakoe K, Ohta M, Saito M
    The Journal of biological chemistry Oct. 1994
  • [Treatment of 71 adult acute lymphoblastic leukemia]
    Yoshida M, Kurata H, Tsunoda S, Iwama A, Suzuki T, Akutsu M, Imagawa S, Tsunoda J, Furukawa Y, Komatsu N
    Gan to kagaku ryoho. Cancer & chemotherapy Sep. 1993
  • [Tumor suppressor genes and their role in abnormal production of leukocytes (leukemogenesis)]
    Furukawa Y
    [Rinsho ketsueki] The Japanese journal of clinical hematology May 1993
  • Transforming growth factor-beta inhibits phosphorylation of the retinoblastoma susceptibility gene product in human monocytic leukemia cell line JOSK-I.
    Furukawa Y, Uenoyama S, Ohta M, Tsunoda A, Griffin JD, Saito M
    The Journal of biological chemistry Aug. 1992
  • [Abnormalities of the retinoblastoma susceptibility gene (RB) in hematologic malignancies].
    Furukawa Y
    Nihon rinsho. Japanese journal of clinical medicine Jun. 1992
  • Treatment of myeloid leukemic cells with the phosphatase inhibitor okadaic acid induces cell cycle arrest at either G1/S or G2/M depending on dose.
    Ishida Y, Furukawa Y, Decaprio JA, Saito M, Griffin JD
    Journal of cellular physiology Mar. 1992
  • The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression.
    DeCaprio JA, Furukawa Y, Ajchenbaum F, Griffin JD, Livingston DM
    Proceedings of the National Academy of Sciences of the United States of America Mar. 1992
  • [The role of cell cycle control genes (the retinoblastoma susceptibility gene and cdc2 gene) in proliferation and differentiation of hematopoietic cells].
    Furukawa Y
    Seikagaku. The Journal of Japanese Biochemical Society Feb. 1992
  • Heterogeneous expression of the product of the retinoblastoma susceptibility gene in primary human leukemia cells.
    Furukawa Y, DeCaprio JA, Belvin M, Griffin JD
    Oncogene Aug. 1991
  • Interleukin 1 production by monocytic leukemia cells and its possible role in coagulation abnormalities.
    Furukawa Y, Ohta M, Miura Y, Saito M
    Leukemia research Jan. 1991
  • Cdc2 Gene Expression at the G1 to S Transition in Human T Lymphocytes.
    Furukawa, Y., Piwnica-Worms, H., Ernst, T.J., Kanakura, Y. and Griffin, J.D.
    Science 250 805-808 Dec. 1990
  • Signal transduction of the human granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors involves tyrosine phosphorylation of a common set of cytoplasmic proteins.
    Kanakura Y, Druker B, Cannistra SA, Furukawa Y, Torimoto Y, Griffin JD
    Blood Aug. 1990
  • Demonstration of interleukin-1 beta transcripts in acute myeloblastic leukemic cells by in situ hybridization.
    Nakamura M, Kanakura Y, Furukawa Y, Ernst TJ, Griffin JD
    Leukemia Jul. 1990
  • Expression and state of phosphorylation of the retinoblastoma susceptibility gene product in cycling and noncycling human hematopoietic cells.
    Furukawa Y, DeCaprio JA, Freedman A, Kanakura Y, Nakamura M, Ernst TJ, Livingston DM, Griffin JD
    Proceedings of the National Academy of Sciences of the United States of America Apr. 1990
  • Expression of a novel 3.5-kb macrophage colony-stimulating factor transcript in human myeloma cells.
    Nakamura M, Merchav S, Carter A, Ernst TJ, Demetri GD, Furukawa Y, Anderson K, Freedman AS, Griffin JD
    Journal of immunology (Baltimore, Md. : 1950) Dec. 1989
  • The Product of Retinoblastoma Susceptibility Gene Has Properties of a Cell Cycle Regulatory Element.
    DeCaprio, J.A., Ludlow, J.W., Lynch, D., Furukawa, Y., Griffin, J., Piwnica-Worms, H., Huang, C.-M. and Livingston, D.M.
    Cell 58 1085-1095 Sep. 1989
  • Antileukemic effect of nitrous oxide in a patient with chronic myelogenous leukemia.
    Ikeda K, Aosaki T, Furukawa Y, Ohta M, Kano Y, Tsuboyama A, Sakamoto S, Miura Y, Sakuraya K, Fuke N
    American journal of hematology Feb. 1989
  • [Treatment of multiple myeloma: renal function in relation to its prognosis]
    Akashi M, Ohta M, Kitagawa S, Furukawa Y, Takeda K, Muroi K, Komatsu N, Ikeda K, Ohsaka A, Yoshida M
    [Rinsho ketsueki] The Japanese journal of clinical hematology Nov. 1988
  • [Primary non-Hodgkin's lymphoma, small lymphocytic type, in the spleen complicating myelodysplastic syndrome].
    Kawashima Y, Furukawa Y, Akutsu M, Yoshida M, Kitagawa S, Sakamoto S, Miura Y
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine Jul. 1988
  • [Treatment of malignant lymphoma in Jichi Medical School Hospital. 3) Treatment of advanced bad-risk lymphoma with the M-CHOP regimen].
    Furukawa Y, Takagi S, Tsuboyama A, Tsunoda S, Komatsu N, Takeda K, Muroi K, Ohsaka A, Miwa A, Yoshida M
    [Rinsho ketsueki] The Japanese journal of clinical hematology Jun. 1988
  • Myelodysplastic syndrome in pregnancy with hematological improvement following delivery.
    Furukawa Y, Enomoto M, Sato Y, Yoshida M, Sakamoto S, Miura Y
    Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society Feb. 1988
  • Cytomegalovirus gastritis as an initial manifestation of a patient with adult T-cell leukemia.
    Furukawa Y, Nakamura H, Sakamoto S, Miura Y
    Acta haematologica Jan. 1988
  • [Treatment of malignant lymphoma: 12 years' experience with 109 patients. 2). Treatment of non-Hodgkin's lymphoma].
    Furukawa Y, Takagi S, Tsuboyama A, Tsunoda S, Akashi M, Komatsu N, Takeda K, Muroi K, Akutsu M, Ohsaka A
    [Rinsho ketsueki] The Japanese journal of clinical hematology Sep. 1987
  • [Treatment of malignant lymphoma: 12 years' experience with 109 patients. 1). Treatment of Hodgkin's disease].
    Furukawa Y, Takagi S, Tsuboyama A, Akashi M, Komatsu N, Takeda K, Muroi K, Ohsaka A, Ohta M, Suda K
    [Rinsho ketsueki] The Japanese journal of clinical hematology Sep. 1987
  • Interleukin-1 derived from human monocytic leukemia cell line JOSK-I acts as an autocrine growth factor.
    Furukawa Y, Ohta M, Miura Y, Saito M
    Biochemical and biophysical research communications Aug. 1987
  • Constitutive production of interleukin 1 by human monocytic leukemia cell line JOSK-I and the production mechanism.
    Furukawa Y, Ohta M, Kasahara T, Miura Y, Saito M
    Cancer research May 1987
  • [The clinical effect of low-dose Ara-C in patients with refractory acute nonlymphocytic leukemia and myelodysplastic syndrome]
    Yoshida M, Tsunoda S, Akutsu M, Furukawa Y, Takeda K, Akashi M, Komatsu N, Muroi K, Ikeda K, Ohsaka A
    Gan to kagaku ryoho. Cancer & chemotherapy Apr. 1987
  • Interleukin-1 producing ability of leukaemia cells and its relationship to morphological diagnosis.
    Furukawa Y, Ohta M, Miura Y, Saito M
    British journal of haematology Jan. 1987
  • Myeloid and erythroid lineage expression of haemopoietic progenitors derived from an abnormal clone in erythroleukaemia.
    Suda T, Sato Y, Furukawa Y, Suda J, Eguchi M, Saito M, Miura Y
    British journal of haematology Dec. 1986
  • Establishment and characterization of four human monocytoid leukemia cell lines (JOSK-I, -S, -M and -K) with capabilities of monocyte-macrophage lineage differentiation and constitutive production of interleukin 1.
    Ohta M, Furukawa Y, Ide C, Akiyama N, Utakoji T, Miura Y, Saito M
    Cancer research Jun. 1986
  • [Essential thrombocythemia--a comparative study on polycythemia vera]
    Ohsaka A, Tsuboyama A, Kano Y, Furukawa Y, Takeda K, Akashi S, Komatsu N, Muroi K, Ohta M, Takagi S
    [Rinsho ketsueki] The Japanese journal of clinical hematology Mar. 1986
  • [High-dose cytosine arabinoside administration in the treatment of refractory leukemia]
    Yoshida M, Furukawa Y, Akashi M, Komatsu N, Takeda K, Muroi K, Ikeda K, Ohsaka A, Ohta M, Suda K
    [Rinsho ketsueki] The Japanese journal of clinical hematology Aug. 1985
  • [Remission induction failures in adult acute non-lymphocytic leukemia]
    Yoshida M, Furukawa Y, Akashi M, Komatsu N, Takeda K, Muroi K, Ikeda K, Ohsaka A, Ohta M, Takagi S
    [Rinsho ketsueki] The Japanese journal of clinical hematology Jun. 1985

Outside Fund Adoption

  • The Role of Cell Cycle Control Genes in Hematopoietic Cell Differentiation
  • The Mechanisms of Cell Death in Hematopoietic Cells
  • Transcriptional Regulation of the Genes involved in hematopoietic differentiation
  • Development of novel cell cycle regulatory drugs
  • Biology of Hematopoietic Stem Cells
Display all
Outside Fund Adoptionclose
  • The Role of Cell Cycle Control Genes in Hematopoietic Cell Differentiation
  • The Mechanisms of Cell Death in Hematopoietic Cells
  • Transcriptional Regulation of the Genes involved in hematopoietic differentiation
  • Development of novel cell cycle regulatory drugs
  • Biology of Hematopoietic Stem Cells

Works

  • Identification of novel p53- binding proteins by BIACORE-MASS
    2001
  • Development of a novel cDNA subtraction method
    1999
  • Application of centrifugal elutriator
    1996
Display all
Worksclose
  • Identification of novel p53- binding proteins by BIACORE-MASS
    2001
  • Development of a novel cDNA subtraction method
    1999
  • Application of centrifugal elutriator
    1996


Copyright c MEDIA FUSION Co.,Ltd. All rights reserved.